Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business UpdateGlobeNewsWire • 9h
Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)GlobeNewsWire • 12/14/23
Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific MeetingsGlobeNewsWire • 10/25/23
Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)GlobeNewsWire • 10/09/23
Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro SummitGlobeNewsWire • 10/06/23
Reneo Pharmaceuticals Announces Presentation and Posters at Mitochondrial Medicine Symposium 2023GlobeNewsWire • 06/15/23
Update -- Reneo Pharmaceuticals to Participate at the Jefferies Healthcare ConferenceGlobeNewsWire • 05/31/23
Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 03/27/23
Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar (REN001) in Primary Mitochondrial MyopathiesGlobeNewsWire • 03/14/23
Reneo Pharmaceuticals to Participate in SVB Securities Global Biopharma ConferenceGlobeNewsWire • 02/02/23
Reneo Pharmaceuticals Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)GlobeNewsWire • 01/31/23
Reneo Pharmaceuticals Announces Poster Presentations at the International Network for Fatty Acid Oxidation Research and Management Annual MeetingGlobeNewsWire • 08/29/22